On the morning of September 23, the 2015 Shenzhen International BT Leadership Summit and the Biological/Life Health Industry Exhibition officially kicked off at the Shenzhen Convention and Exhibition Center. Well-known experts, scholars and entrepreneurs in the field of biological and life health at home and abroad gathered to discuss the development of the industry. The road ahead.
Xu Anliang, Deputy Mayor of Shenzhen Municipal People’s Government of ISKCON 2015 BT Summit as the host of the opening ceremony, James Greenwood, President and CEO of the United States Global Biotechnology Industry Organization ("BIO"), and Cai Muling, Deputy Director of the Guangdong Provincial Development and Reform Commission , Xu Qin, deputy secretary of the Shenzhen Municipal Party Committee and Mayor, attended the opening ceremony and delivered an opening speech.
Xu Qin said at the opening ceremony that the biology and life health industries are key areas for innovation and development under the new normal. Shenzhen now has major scientific and technological facilities such as the National Gene Bank, and has built more than 200 innovative carriers such as key laboratories in the field of biotechnology. In the future, Shenzhen will focus on promoting the integrated development of the information technology industry and the biotechnology industry, combining the biological and life health industry with the medical and health "Three Peoples Project", building a platform for biotechnology and medical technology, and promoting biotechnology and medical systems. Positively interactive development with the life and health industry.
After the successful holding of the first BT Leadership Summit last year, the BT Leadership Summit has become the highest-level domestic and internationally specialized event in the biological and life and health fields. It has received extensive attention from the industry and all walks of life. Under the expectation of everyone, the 2015 Shenzhen International The BT Leaders Summit officially opened today, focusing on the frontiers of biotechnology and industrial development, accelerating the integration of bio-resources, technology, industry and capital, and playing the role of a vane in the biological and life-health industries.
Ishikoning participated in this exhibition and received an enthusiastic response. Over the years, ISKCON has been committed to the development and application of ACTL targeted anti-tumor cell immune technology, published dozens of related articles, obtained 18 domestic and foreign patents, and passed a number of international standardization certifications. It has established scientific research and application cooperation relations with more than 50 large domestic hospitals, and its service network covers 2/3 of the domestic provinces, and has established bases overseas. ISKCON will continue to benefit patients and give back to society through innovative technologies.
Staff explain ACTL technology
